NEW YORK (GenomeWeb News) — Cepheid today said it has acquired PCR diagnostics company Sangtec Molecular Diagnostics from Altana Pharma for around $27 million in cash.
Cepheid CEO John Bishop said the acquisition gives the company a “relatively complete line of products for managing infections of immunocompromised patients.”
Bishop said the firm will also provide Cepheid with an established reagent-manufacturing base in Europe.
Cepheid said it will integrate Sangtec’s PCR diagnostic kits into its European and US in vitro product line, which will now offer assays for cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, hepatitis B virus, Varicella zoster virus, BK virus and Aspergillus.
Sangtec brings with it an R&D team with real-time PCR experience and an experienced manufacturing team as well, Bishop added.
Sangtec generated around $8 million in revenue last year and has 59 employees, Cepheid said.